|
|
|
Volumn 19, Issue 13 Suppl 5, 2005, Pages 4-
|
|
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIDERMAL GROWTH FACTOR RECEPTOR;
HEAT SHOCK PROTEIN 90;
MONOCLONAL ANTIBODY;
PERTUZUMAB;
PROTEIN KINASE INHIBITOR;
TRASTUZUMAB;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
BREAST TUMOR;
DRUG ANTAGONISM;
FEMALE;
HUMAN;
METABOLISM;
PATHOLOGY;
CELL PROLIFERATION;
DISEASE COURSE;
DRUG RESISTANCE;
GENE THERAPY;
MULTIMODALITY CANCER THERAPY;
REVIEW;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
ANTIBODIES, MONOCLONAL;
CELL PROLIFERATION;
COMBINED MODALITY THERAPY;
DISEASE PROGRESSION;
DRUG RESISTANCE, NEOPLASM;
GENE THERAPY;
HSP90 HEAT-SHOCK PROTEINS;
PROTEIN KINASE INHIBITORS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 66149110017
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|
